SrasV1, Ncbi, Merge, bibRecord, 000A83

Immunogenicity of SARS inactivated vaccine in BALB/c mice.

Identifieur interne : 000A83 ( Ncbi/Merge ); précédent : 000A82; suivant : 000A84

Immunogenicity of SARS inactivated vaccine in BALB/c mice.

Auteurs : Sheng Xiong [République populaire de Chine] ; Yi-Fei Wang ; Mei-Ying Zhang ; Xin-Jian Liu ; Chuan-Hai Zhang ; Shi-Sheng Liu ; Chui-Wen Qian ; Jiu-Xiang Li ; Jia-Hai Lu ; Zhuo-Yue Wan ; Huan-Yin Zheng ; Xin-Ge Yan ; Min-Jie Meng ; Jiang-Lin Fan

Source :

Immunology letters [ 0165-2478 ] ; 2004.

RBID : pubmed:15388253

Descripteurs français

English descriptors

KwdEn :
- Animals, Antibodies, Viral (blood), Antibodies, Viral (immunology), Antibody Specificity, Antigens, Viral (immunology), Immune Sera (immunology), Immunoglobulin G (blood), Immunoglobulin G (immunology), Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Vaccines, Inactivated (immunology), Viral Vaccines (immunology).
MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , immunology : Antibodies, Viral, Antigens, Viral, Immune Sera, Immunoglobulin G, Vaccines, Inactivated, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Antibody Specificity, Kinetics, Mice, Mice, Inbred BALB C, Neutralization Tests.

Abstract

Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.

DOI: 10.1016/j.imlet.2004.06.014
PubMed: 15388253

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002B45
to stream PubMed, to step Curation: 002B45
to stream PubMed, to step Checkpoint: 002C54

Links to Exploration step

pubmed:15388253

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title>
<author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630</wicri:regionArea>
<placeName><settlement type="city">Jiangmen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name>
</author>
<author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name>
</author>
<author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name>
</author>
<author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name>
</author>
<author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name>
</author>
<author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name>
</author>
<author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name>
</author>
<author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name>
</author>
<author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name>
</author>
<author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name>
</author>
<author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name>
</author>
<author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name>
</author>
<author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15388253</idno>
<idno type="pmid">15388253</idno>
<idno type="doi">10.1016/j.imlet.2004.06.014</idno>
<idno type="wicri:Area/PubMed/Corpus">002B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B45</idno>
<idno type="wicri:Area/PubMed/Curation">002B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B45</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C54</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C54</idno>
<idno type="wicri:Area/Ncbi/Merge">000A83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity of SARS inactivated vaccine in BALB/c mice.</title>
<author><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630</wicri:regionArea>
<placeName><settlement type="city">Jiangmen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name>
</author>
<author><name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name>
</author>
<author><name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name>
</author>
<author><name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name>
</author>
<author><name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name>
</author>
<author><name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name>
</author>
<author><name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name>
</author>
<author><name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name>
</author>
<author><name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name>
</author>
<author><name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name>
</author>
<author><name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name>
</author>
<author><name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name>
</author>
<author><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name>
</author>
</analytic>
<series><title level="j">Immunology letters</title>
<idno type="ISSN">0165-2478</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibodies, Viral (immunology)</term>
<term>Antibody Specificity</term>
<term>Antigens, Viral (immunology)</term>
<term>Immune Sera (immunology)</term>
<term>Immunoglobulin G (blood)</term>
<term>Immunoglobulin G (immunology)</term>
<term>Kinetics</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Antigènes viraux (immunologie)</term>
<term>Cinétique</term>
<term>Immunoglobuline G (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Spécificité des anticorps</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Sérums immuns (immunologie)</term>
<term>Tests de neutralisation</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Antigens, Viral</term>
<term>Immune Sera</term>
<term>Immunoglobulin G</term>
<term>Vaccines, Inactivated</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Antigènes viraux</term>
<term>Immunoglobuline G</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Sérums immuns</term>
<term>Vaccins antiviraux</term>
<term>Vaccins inactivés</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antibody Specificity</term>
<term>Kinetics</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Neutralization Tests</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cinétique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Spécificité des anticorps</term>
<term>Tests de neutralisation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15388253</PMID>
<DateCompleted><Year>2005</Year>
<Month>04</Month>
<Day>20</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-2478</ISSN>
<JournalIssue CitedMedium="Print"><Volume>95</Volume>
<Issue>2</Issue>
<PubDate><Year>2004</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Immunology letters</Title>
<ISOAbbreviation>Immunol. Lett.</ISOAbbreviation>
</Journal>
<ArticleTitle>Immunogenicity of SARS inactivated vaccine in BALB/c mice.</ArticleTitle>
<Pagination><MedlinePgn>139-43</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a serious infectious threat to public health. To create a novel trial vaccine and evaluate its potency, we attempted to generate a SARS inactivated vaccine using SARS coronavirus (SARS-CoV) strain F69 treated with formaldehyde and mixed with Al(OH)3. Three doses of the vaccine were used to challenge three groups of BALB/c mice. We found that the mice exhibited specific IgM on day 4 and IgG on day 8. The peak titers of IgG were at day 47 in low-dose group (1:19,200) and high-dose group (1:38,400) whereas in middle-dose group (1:19,200), the peak was at day 40. On day 63, the IgG levels reached a plateau. Neutralization assay demonstrated that the antisera could protect Vero-E6 cells from SARS-CoV's infection. Analysis of the antibody specificity revealed that the mouse antisera contained a mixture of antibodies specifically against the structure proteins of SARS-CoV. Furthermore, the mouse antisera conferred higher amount of antibodies against protein N, polypeptide S4 and S2 than those of proteins M and 3CL. These findings suggest that the inactivated SARS-CoV could preserve its antigenicity and the inactivated vaccine can stimulate mice to produce high levels of antibodies with neutralization activity. Results also suggest that polypeptides originating from protein N or S might be a potential target for the generation of a recombinant SARS vaccine.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiong</LastName>
<ForeName>Sheng</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Biomedical Research & Development Center, Floor 5, Building of Biology, Jinan University, Guangzhou 510630, PR China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yi-Fei</ForeName>
<Initials>YF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Mei-Ying</ForeName>
<Initials>MY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Xin-Jian</ForeName>
<Initials>XJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Chuan-Hai</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Shi-Sheng</ForeName>
<Initials>SS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Qian</LastName>
<ForeName>Chui-Wen</ForeName>
<Initials>CW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jiu-Xiang</ForeName>
<Initials>JX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lu</LastName>
<ForeName>Jia-Hai</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wan</LastName>
<ForeName>Zhuo-Yue</ForeName>
<Initials>ZY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zheng</LastName>
<ForeName>Huan-Yin</ForeName>
<Initials>HY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yan</LastName>
<ForeName>Xin-Ge</ForeName>
<Initials>XG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Meng</LastName>
<ForeName>Min-Jie</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fan</LastName>
<ForeName>Jiang-lin</ForeName>
<Initials>JL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Immunol Lett</MedlineTA>
<NlmUniqueID>7910006</NlmUniqueID>
<ISSNLinking>0165-2478</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007106">Immune Sera</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007106" MajorTopicYN="N">Immune Sera</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year>
<Month>05</Month>
<Day>31</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2004</Year>
<Month>06</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>06</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>9</Month>
<Day>25</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>9</Month>
<Day>25</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId>
<ArticleId IdType="doi">10.1016/j.imlet.2004.06.014</ArticleId>
<ArticleId IdType="pii">S0165-2478(04)00174-9</ArticleId>
<ArticleId IdType="pmc">PMC7112924</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Avian Pathol. 2003 Dec;32(6):567-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14676007</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2004 Mar 12;303(5664):1666-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14752165</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 2003 Dec;283(1-2):45-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14659898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>New Microbiol. 2003 Apr;26(2):151-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12737196</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2003 Nov 7;21(31):4519-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14575762</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Can J Vet Res. 2002 Oct;66(4):278-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12418784</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2002 Mar 20;84(1-2):101-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11900843</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 1992;10(4):214-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1348595</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2536-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14983044</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2001 Sep 14;19(32):4635-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11535311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Guangdong</li>
</region>
<settlement><li>Jiangmen</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Fan, Jiang Lin" sort="Fan, Jiang Lin" uniqKey="Fan J" first="Jiang-Lin" last="Fan">Jiang-Lin Fan</name>
<name sortKey="Li, Jiu Xiang" sort="Li, Jiu Xiang" uniqKey="Li J" first="Jiu-Xiang" last="Li">Jiu-Xiang Li</name>
<name sortKey="Liu, Shi Sheng" sort="Liu, Shi Sheng" uniqKey="Liu S" first="Shi-Sheng" last="Liu">Shi-Sheng Liu</name>
<name sortKey="Liu, Xin Jian" sort="Liu, Xin Jian" uniqKey="Liu X" first="Xin-Jian" last="Liu">Xin-Jian Liu</name>
<name sortKey="Lu, Jia Hai" sort="Lu, Jia Hai" uniqKey="Lu J" first="Jia-Hai" last="Lu">Jia-Hai Lu</name>
<name sortKey="Meng, Min Jie" sort="Meng, Min Jie" uniqKey="Meng M" first="Min-Jie" last="Meng">Min-Jie Meng</name>
<name sortKey="Qian, Chui Wen" sort="Qian, Chui Wen" uniqKey="Qian C" first="Chui-Wen" last="Qian">Chui-Wen Qian</name>
<name sortKey="Wan, Zhuo Yue" sort="Wan, Zhuo Yue" uniqKey="Wan Z" first="Zhuo-Yue" last="Wan">Zhuo-Yue Wan</name>
<name sortKey="Wang, Yi Fei" sort="Wang, Yi Fei" uniqKey="Wang Y" first="Yi-Fei" last="Wang">Yi-Fei Wang</name>
<name sortKey="Yan, Xin Ge" sort="Yan, Xin Ge" uniqKey="Yan X" first="Xin-Ge" last="Yan">Xin-Ge Yan</name>
<name sortKey="Zhang, Chuan Hai" sort="Zhang, Chuan Hai" uniqKey="Zhang C" first="Chuan-Hai" last="Zhang">Chuan-Hai Zhang</name>
<name sortKey="Zhang, Mei Ying" sort="Zhang, Mei Ying" uniqKey="Zhang M" first="Mei-Ying" last="Zhang">Mei-Ying Zhang</name>
<name sortKey="Zheng, Huan Yin" sort="Zheng, Huan Yin" uniqKey="Zheng H" first="Huan-Yin" last="Zheng">Huan-Yin Zheng</name>
</noCountry>
<country name="République populaire de Chine"><region name="Guangdong"><name sortKey="Xiong, Sheng" sort="Xiong, Sheng" uniqKey="Xiong S" first="Sheng" last="Xiong">Sheng Xiong</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000A83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:15388253
   |texte=   Immunogenicity of SARS inactivated vaccine in BALB/c mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:15388253" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Immunogenicity of SARS inactivated vaccine in BALB/c mice.

Immunogenicity of SARS inactivated vaccine in BALB/c mice.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki